What was the overall valuation of the US ophthalmoplegia market in 2024?

The overall market valuation was $218.4 Million in 2024. Read More

What is the projected market valuation for the US ophthalmoplegia market by 2035?

The projected valuation for 2035 is $523.94 Million. Read More

What is the expected CAGR for the US ophthalmoplegia market during the forecast period 2025 - 2035?

The expected CAGR for the market during this period is 8.28%. Read More

Which companies are considered key players in the US ophthalmoplegia market?

Key players include Novartis, Bausch Health, Allergan, Regeneron Pharmaceuticals, Roche, Santen Pharmaceutical, Horizon Therapeutics, and Aerie Pharmaceuticals. Read More

What are the main types of ophthalmoplegia and their market valuations?

The main types include Congenital Ophthalmoplegia ($43.76 - $104.12 Million), Acquired Ophthalmoplegia ($65.76 - $155.12 Million), Botulism Ophthalmoplegia ($32.88 - $77.56 Million), and Thyroid Eye Disease ($76.0 - $187.14 Million). Read More

What symptoms are associated with ophthalmoplegia and their market values?

Symptoms include Diplopia ($40.0 - $100.0 Million), Ptosis ($30.0 - $70.0 Million), Strabismus ($50.0 - $120.0 Million), and Limited Eye Movement ($98.4 - $233.94 Million). Read More

What treatment types are available for ophthalmoplegia and their market valuations?

Treatment types include Surgical Intervention ($40.0 - $100.0 Million), Medication ($100.0 - $250.0 Million), and Physical Therapy ($78.4 - $173.94 Million). Read More

What are the end-user segments in the US ophthalmoplegia market?

End-user segments include Hospitals ($80.0 - $200.0 Million), Ophthalmology Clinics ($70.0 - $150.0 Million), and Home Care Settings ($68.4 - $173.94 Million). Read More

How does the market for ophthalmoplegia appear to be evolving?

The market appears to be growing steadily, with a projected increase in valuation from $218.4 Million in 2024 to $523.94 Million by 2035. Read More

What factors might influence the growth of the US ophthalmoplegia market?

Factors influencing growth may include advancements in treatment options, increasing awareness of ophthalmoplegia, and the rising prevalence of related conditions. Read More

US Ophthalmoplegia Market

ID: MRFR/Pharma/18449-HCR

100 Pages

Satyendra Maurya

Last Updated: April 06, 2026

US Ophthalmoplegia Market Research Report By Types (External Ophthalmoplegia, Internuclear Ophthalmoplegia), By Treatment (Surgery, Drug Treatment) and By End Users (Hospital & Clinics, Ambulatory Clinics) - Growth & Industry Forecast 2025 To 2035

Summary Table of Contents Segmentation Download PDF

Certified Researchers

Customize Report

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1. 1.1 EXECUTIVE SUMMARY
  1. 1.1.1 Market Overview
  2. 1.1.2 Key Findings
  3. 1.1.3 Market Segmentation
  4. 1.1.4 Competitive Landscape
  5. 1.1.5 Challenges and Opportunities
  6. 1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
1. 2.1 MARKET INTRODUCTION
  1. 2.1.1 Definition
  2. 2.1.2 Scope of the study
    1. 2.1.2.1 Research Objective
    2. 2.1.2.2 Assumption
    3. 2.1.2.3 Limitations
2. 2.2 RESEARCH METHODOLOGY
  1. 2.2.1 Overview
  2. 2.2.2 Data Mining
  3. 2.2.3 Secondary Research
  4. 2.2.4 Primary Research
    1. 2.2.4.1 Primary Interviews and Information Gathering Process
    2. 2.2.4.2 Breakdown of Primary Respondents
  5. 2.2.5 Forecasting Model
  6. 2.2.6 Market Size Estimation
    1. 2.2.6.1 Bottom-Up Approach
    2. 2.2.6.2 Top-Down Approach
  7. 2.2.7 Data Triangulation
  8. 2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
1. 3.1 MARKET DYNAMICS
  1. 3.1.1 Overview
  2. 3.1.2 Drivers
  3. 3.1.3 Restraints
  4. 3.1.4 Opportunities
2. 3.2 MARKET FACTOR ANALYSIS
  1. 3.2.1 Value chain Analysis
  2. 3.2.2 Porter's Five Forces Analysis
    1. 3.2.2.1 Bargaining Power of Suppliers
    2. 3.2.2.2 Bargaining Power of Buyers
    3. 3.2.2.3 Threat of New Entrants
    4. 3.2.2.4 Threat of Substitutes
    5. 3.2.2.5 Intensity of Rivalry
  3. 3.2.3 COVID-19 Impact Analysis
    1. 3.2.3.1 Market Impact Analysis
    2. 3.2.3.2 Regional Impact
    3. 3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
1. 4.1 Industrial Automation & Equipment, BY Type of Ophthalmoplegia (USD Million)
  1. 4.1.1 Congenital Ophthalmoplegia
  2. 4.1.2 Acquired Ophthalmoplegia
  3. 4.1.3 Botulism Ophthalmoplegia
  4. 4.1.4 Thyroid Eye Disease
2. 4.2 Industrial Automation & Equipment, BY Symptoms (USD Million)
  1. 4.2.1 Diplopia
  2. 4.2.2 Ptosis
  3. 4.2.3 Strabismus
  4. 4.2.4 Limited Eye Movement
3. 4.3 Industrial Automation & Equipment, BY Treatment Type (USD Million)
  1. 4.3.1 Surgical Intervention
  2. 4.3.2 Medication
  3. 4.3.3 Physical Therapy
4. 4.4 Industrial Automation & Equipment, BY End User (USD Million)
  1. 4.4.1 Hospitals
  2. 4.4.2 Ophthalmology Clinics
  3. 4.4.3 Home Care Settings
5 SECTION V: COMPETITIVE ANALYSIS
1. 5.1 Competitive Landscape
  1. 5.1.1 Overview
  2. 5.1.2 Competitive Analysis
  3. 5.1.3 Market share Analysis
  4. 5.1.4 Major Growth Strategy in the Industrial Automation & Equipment
  5. 5.1.5 Competitive Benchmarking
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Industrial Automation & Equipment
  7. 5.1.7 Key developments and growth strategies
    1. 5.1.7.1 New Product Launch/Service Deployment
    2. 5.1.7.2 Merger & Acquisitions
    3. 5.1.7.3 Joint Ventures
  8. 5.1.8 Major Players Financial Matrix
    1. 5.1.8.1 Sales and Operating Income
    2. 5.1.8.2 Major Players R&D Expenditure. 2023
2. 5.2 Company Profiles
  1. 5.2.1 Novartis (CH)
    1. 5.2.1.1 Financial Overview
    2. 5.2.1.2 Products Offered
    3. 5.2.1.3 Key Developments
    4. 5.2.1.4 SWOT Analysis
    5. 5.2.1.5 Key Strategies
  2. 5.2.2 Bausch Health (CA)
    1. 5.2.2.1 Financial Overview
    2. 5.2.2.2 Products Offered
    3. 5.2.2.3 Key Developments
    4. 5.2.2.4 SWOT Analysis
    5. 5.2.2.5 Key Strategies
  3. 5.2.3 Allergan (IE)
    1. 5.2.3.1 Financial Overview
    2. 5.2.3.2 Products Offered
    3. 5.2.3.3 Key Developments
    4. 5.2.3.4 SWOT Analysis
    5. 5.2.3.5 Key Strategies
  4. 5.2.4 Regeneron Pharmaceuticals (US)
    1. 5.2.4.1 Financial Overview
    2. 5.2.4.2 Products Offered
    3. 5.2.4.3 Key Developments
    4. 5.2.4.4 SWOT Analysis
    5. 5.2.4.5 Key Strategies
  5. 5.2.5 Roche (CH)
    1. 5.2.5.1 Financial Overview
    2. 5.2.5.2 Products Offered
    3. 5.2.5.3 Key Developments
    4. 5.2.5.4 SWOT Analysis
    5. 5.2.5.5 Key Strategies
  6. 5.2.6 Santen Pharmaceutical (JP)
    1. 5.2.6.1 Financial Overview
    2. 5.2.6.2 Products Offered
    3. 5.2.6.3 Key Developments
    4. 5.2.6.4 SWOT Analysis
    5. 5.2.6.5 Key Strategies
  7. 5.2.7 Horizon Therapeutics (IE)
    1. 5.2.7.1 Financial Overview
    2. 5.2.7.2 Products Offered
    3. 5.2.7.3 Key Developments
    4. 5.2.7.4 SWOT Analysis
    5. 5.2.7.5 Key Strategies
  8. 5.2.8 Aerie Pharmaceuticals (US)
    1. 5.2.8.1 Financial Overview
    2. 5.2.8.2 Products Offered
    3. 5.2.8.3 Key Developments
    4. 5.2.8.4 SWOT Analysis
    5. 5.2.8.5 Key Strategies
3. 5.3 Appendix
  1. 5.3.1 References
  2. 5.3.2 Related Reports
6 LIST OF FIGURES
1. 6.1 MARKET SYNOPSIS
2. 6.2 US MARKET ANALYSIS BY TYPE OF OPHTHALMOPLEGIA
3. 6.3 US MARKET ANALYSIS BY SYMPTOMS
4. 6.4 US MARKET ANALYSIS BY TREATMENT TYPE
5. 6.5 US MARKET ANALYSIS BY END USER
6. 6.6 KEY BUYING CRITERIA OF INDUSTRIAL AUTOMATION & EQUIPMENT
7. 6.7 RESEARCH PROCESS OF MRFR
8. 6.8 DRO ANALYSIS OF INDUSTRIAL AUTOMATION & EQUIPMENT
9. 6.9 DRIVERS IMPACT ANALYSIS: INDUSTRIAL AUTOMATION & EQUIPMENT
10. 6.10 RESTRAINTS IMPACT ANALYSIS: INDUSTRIAL AUTOMATION & EQUIPMENT
11. 6.11 SUPPLY / VALUE CHAIN: INDUSTRIAL AUTOMATION & EQUIPMENT
12. 6.12 INDUSTRIAL AUTOMATION & EQUIPMENT, BY TYPE OF OPHTHALMOPLEGIA, 2024 (% SHARE)
13. 6.13 INDUSTRIAL AUTOMATION & EQUIPMENT, BY TYPE OF OPHTHALMOPLEGIA, 2024 TO 2035 (USD Million)
14. 6.14 INDUSTRIAL AUTOMATION & EQUIPMENT, BY SYMPTOMS, 2024 (% SHARE)
15. 6.15 INDUSTRIAL AUTOMATION & EQUIPMENT, BY SYMPTOMS, 2024 TO 2035 (USD Million)
16. 6.16 INDUSTRIAL AUTOMATION & EQUIPMENT, BY TREATMENT TYPE, 2024 (% SHARE)
17. 6.17 INDUSTRIAL AUTOMATION & EQUIPMENT, BY TREATMENT TYPE, 2024 TO 2035 (USD Million)
18. 6.18 INDUSTRIAL AUTOMATION & EQUIPMENT, BY END USER, 2024 (% SHARE)
19. 6.19 INDUSTRIAL AUTOMATION & EQUIPMENT, BY END USER, 2024 TO 2035 (USD Million)
20. 6.20 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
1. 7.1 LIST OF ASSUMPTIONS
7.1.1
1. 7.2 US MARKET SIZE ESTIMATES; FORECAST
  1. 7.2.1 BY TYPE OF OPHTHALMOPLEGIA, 2025-2035 (USD Million)
  2. 7.2.2 BY SYMPTOMS, 2025-2035 (USD Million)
  3. 7.2.3 BY TREATMENT TYPE, 2025-2035 (USD Million)
  4. 7.2.4 BY END USER, 2025-2035 (USD Million)
2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.3.1
1. 7.4 ACQUISITION/PARTNERSHIP
7.4.1

Certified Researchers

Customize Report

US Industrial Automation & Equipment Market Segmentation

Industrial Automation & Equipment By Type of Ophthalmoplegia (USD Million, 2025-2035)

Congenital Ophthalmoplegia
Acquired Ophthalmoplegia
Botulism Ophthalmoplegia
Thyroid Eye Disease

Industrial Automation & Equipment By Symptoms (USD Million, 2025-2035)

Diplopia
Ptosis
Strabismus
Limited Eye Movement

Industrial Automation & Equipment By Treatment Type (USD Million, 2025-2035)

Surgical Intervention
Medication
Physical Therapy

Industrial Automation & Equipment By End User (USD Million, 2025-2035)

Hospitals
Ophthalmology Clinics
Home Care Settings

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”